Incremental Value of 111-In Pentetreotide SPECT/CT Fusion Imaging of Neuroendocrine Tumors
- 1 March 2010
- journal article
- research article
- Published by Elsevier in Academic Radiology
- Vol. 17 (3), 291-297
- https://doi.org/10.1016/j.acra.2009.08.015
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- SPECT/CTJournal of Nuclear Medicine, 2008
- SPECT/CT Imaging: Clinical Utility of an Emerging TechnologyRadioGraphics, 2008
- Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECTNuclear Medicine Communications, 2007
- Imaging of Neuroendocrine TumorsSeminars in Nuclear Medicine, 2006
- Image fusion analysis of 99mTc-HYNIC-Tyr3-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-Pentetreotide scintigraphyRevista Española de Medicina Nuclear, 2005
- Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumoursEuropean Radiology, 2004
- SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumoursClinical Endocrinology, 2003
- Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasmsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993